The quest for an anti-arrhythmic drug against atrial fibrillation that combines efficacy with safety.
Vos
Marc A
MA
D000200:Action Potentials / Q000187:drug effects / Q000502:physiology*; D000818:Animals; D001281:Atrial Fibrillation / Q000188:drug therapy*; D053961:Azabicyclo Compounds / Q000008:administration & dosage*; D002219:Carbamates / Q000008:administration & dosage*; D002478:Cells, Cultured; D004285:Dogs; D006329:Heart Conduction System / Q000187:drug effects / Q000502:physiology*; D032383:Myocytes, Cardiac / Q000187:drug effects / Q000502:physiology*; D011817:Rabbits; D012964:Sodium / Q000378:metabolism*; D026941:Sodium Channel Blockers / Q000008:administration & dosage; D016276:Ventricular Function / Q000187:drug effects*
D053961:Azabicyclo Compounds; D002219:Carbamates; D026941:Sodium Channel Blockers; C550721:tert-butyl (2-(7-(2-(4-cyano-2-fluorophenoxy)ethyl)-9-oxa-3,7-diazabicyclo(3.3.1)non3-yl)ethyl)carbamate; D012964:Sodium